EDGAR Filing Documents for 0001176256-09-000225

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:

SEC Accession No. 0001176256-09-000225

Filing Date

2009-03-13

Accepted

2009-03-13 12:54:34

Documents

Period of Report

2008-12-31

Document Format Files

Seq	Description	Document	Type	Size
1	ANNUAL REPORT	nymox20fdec31.htm	20-F	1235721
2	CERTIFICATION	exhibit12-a.htm	EX-12.(A)	5803
3	CERTIFICATION	exhibit12-b.htm	EX-12.(B)	5734
4	CERTIFICATION	exhibit13-a.htm	EX-13.(A)	2600
5	CERTIFICATION	exhibit13-b.htm	EX-13.(B)	2586
6	GRAPHIC	nymoxafsx2x1.jpg	GRAPHIC	1750
7	GRAPHIC	nymoxafsx4x1.jpg	GRAPHIC	1308
	Complete submission text file	0001176256-09-000225.txt		1258488

Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2

Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 5143323222

NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-12033 | Film No.: 09678847
SIC: 2835 In Vitro & In Vivo Diagnostic Substances